Galux
Galux is a South Korean biotech company developing the AI-native GaluxDesign platform for de novo protein and antibody therapeutics design, serving global pharmaceutical companies through co-development partnerships and platform services targeting cancer, autoimmune, and rare diseases.
- Company typePrivate
- Founded2020
- HeadquartersDogokdong, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Galux does
Galux Inc. (갤럭스 주식회사) is a South Korean privately held biotechnology company founded in 2020, headquartered in Seoul with an R&D wet-lab center in Gangseo-gu. The company develops AI-driven protein therapeutics design technology centered on its proprietary platform GaluxDesign, which integrates artificial intelligence with physics-based first principles to enable modality-agnostic de novo design of therapeutic proteins, with demonstrated strength in de novo antibody design.
The GaluxDesign platform has been validated through peer-reviewed publications in Science Advances (T-SCAPE immunogenicity scoring co-developed with Seoul National University) and bioRxiv, and demonstrated the broadest target coverage in a comparative de novo antibody design study, achieving experimentally validated binders for 8 of 9 publicly comparable targets. The company has extended platform capabilities to challenging target classes including GPCRs and ion channels, with reported high consistency between AI-designed antibodies and cryo-EM experimental structures.
Galux operates as a B2B biotech through a partnership-driven go-to-market model, generating revenue via co-development agreements, research partnerships, and platform services with global and regional pharmaceutical companies. Named partners include Boehringer Ingelheim, Celltrion, LG Chem, HanAll Biopharma, Y-Biologics, GC Biopharma, AimedBio, OliX, ISU Abxis, and Woojung Bio, spanning cancer, autoimmune, rare disease, siRNA delivery, and blood-brain barrier-crossing therapeutic programs. The company is venture-backed with $47 million raised across a 2021 strategic round (Kakao Brain), 2022 Series A, and February 2026 Series B led by InterVest and DAYLI Partners, with 11-50 employees and revenue figures undisclosed.
Galux firmographics
Firmographics- Name
- Galux
- Legal name
- Galux Inc. (갤럭스 주식회사)
- Website
- https://galux.co.kr
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Galux is a South Korean biotech company developing the AI-native GaluxDesign platform for de novo protein and antibody therapeutics design, serving global pharmaceutical companies through co-development partnerships and platform services targeting cancer, autoimmune, and rare diseases.
- Ownership category
- akta.pro rank
Galux industry classification
Industry- Product category
- AI Drug Discovery / Computational Protein Design
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Galux is headquartered
LocationHeadquarters
- HQ city
- Dogokdong
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Galux business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Co-development and Research Partnerships: Galux generates revenue through strategic co-development agreements with pharmaceutical companies. These partnerships involve joint research agreements where Galux provides AI-driven protein design capabilities while partners contribute to preclinical/clinical development, funding, and commercialization. Examples include collaborations with Boehringer Ingelheim, Celltrion, LG Chem, and others.
- AI Platform Licensing and Services: Revenue generated from licensing GaluxDesign platform technology and providing AI protein design services to pharmaceutical partners for specific therapeutic programs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Galux product offering
Product offeringCore offering
Galux develops and operates GaluxDesign, a proprietary AI platform that integrates artificial intelligence with physics-based principles to design therapeutic proteins from scratch (de novo protein design). The platform is modality-agnostic and is delivered to pharmaceutical partners through co-development agreements, joint research collaborations, and licensing arrangements to accelerate discovery of antibody therapeutics for autoimmune diseases, cancer, and rare/incurable diseases.
Product overview
Galux develops AI-driven protein therapeutics design as a single unified offering centered on its GaluxDesign platform. This proprietary AI platform integrates artificial intelligence with physics-based first principles to enable de novo design of therapeutic proteins, particularly antibodies. The platform is modality-agnostic and supports design across challenging target classes including GPCRs and ion channels. Galux also offers T-SCAPE, a complementary T cell immunogenicity scoring tool developed with Seoul National University, which provides safety assessment for designed therapeutics. The company operates through research collaborations and partnerships with pharmaceutical companies, providing access to its platform capabilities for joint drug development programs rather than licensing the software as a standalone product.
Differentiator
Problem solved
Functional benefit
Brands
- GaluxDesign: Galux's proprietary AI platform for de novo protein design that integrates artificial intelligence and physical principles for antibody and protein therapeutics design.
Products and services
- GaluxDesign Proprietary AI platform that integrates artificial intelligence with physics-based first principles to design therapeutic proteins from scratch (de novo design). The platform is modality-agnostic and has demonstrated unprecedented accuracy in de novo antibody design, including challenging target classes such as GPCRs and ion channels. Delivered to pharmaceutical partners through co-development agreements and joint research collaborations.
- T-SCAPE T-SCAPE (T cell immunogenicity scoring via cross-domain aided predictive engine) is an AI tool developed in collaboration with Seoul National University for predicting and scoring the immunogenicity of drug candidates, supporting safety assessment of designed therapeutics.
Quantifiable outcome
- Achieved broadest target coverage in de novo antibody design - 8 out of 9 targets validated vs competitors' lower success rates
- +3 more outcomes
Companies that use Galux
Customer profileNamed customers11 records
Segments2 records
Ideal customer profiles1 record
Galux technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Galux partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and flagship.
- AimedBiocoreInvestment and joint research agreement to develop a blood-brain barrier-crossing protein delivery platform combining Galux's AI-based protein design with antibody drug development with AimedBio's expanding ADC development capabilities. The partnership aims to address a major technical hurdle in brain disease treatment.
- GC BiopharmacoreGalux partnered with GC Biopharma to develop antibody therapeutics for autoimmune diseases using Galux's AI platform for de novo antibody design and GC Biopharma's R&D capabilities in oncology, immunology, and rare diseases. Galux designs and optimizes AI-generated antibody candidates while GC Biopharma conducts experimental validation.
- OliXcorePartnership for AI-based siRNA delivery platform development combining Galux's protein design AI with OliX's siRNA delivery technology.
- Boehringer IngelheimflagshipGalux signed a joint research agreement with Boehringer Ingelheim to evaluate whether Galux's AI platform can consistently design functional proteins from scratch using the GaluxDesign platform. The collaboration tests whether the system can produce proteins difficult to generate through conventional discovery methods by encoding functional requirements directly into the design process. Financial terms and specific therapeutic targets were not disclosed.
- CelltrionflagshipKorean biopharma company Celltrion partnered with Galux to develop multispecific antibody drugs for autoimmune diseases. Galux focuses on AI-based antibody design while Celltrion handles preclinical and clinical development, aiming to accelerate drug development and improve success rates.
- ISU AbxiscoreCollaboration to develop next-generation therapies for rare diseases using Galux's AI-driven drug discovery capabilities.
- Y-BiologicscoreAI-based immune anticancer treatment co-development partnership combining Galux's protein design AI with Y-Biologics' expertise.
- Woojung BiocoreStrategic partnership to accelerate AI-driven therapeutics development combining both companies' capabilities.
- HanAll BiopharmacoreStrategic collaboration to develop AI-designed antibody therapeutics for cancer using Galux's de novo antibody design capabilities.
- LG ChemcoreJoint drug development programs for cancer therapeutics using Galux's AI-driven protein design platform.
- Seoul National UniversitycoreCo-development of T-SCAPE, an AI for predicting immunogenicity of drug candidates, combining academic research capabilities with industry application.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Galux competitors and assessment
Company assessmentDirect peers
- Nabla Bio: US-based AI biotech developing JAM-2 for de novo antibody and protein design. Most directly comparable peer — Galux's May 2026 comparative benchmark explicitly measured GaluxDesign against Nabla Bio's JAM-2 on the same 9 publicly known targets.
- Chai Discovery: AI-driven protein design company behind the Chai-2 platform. Named alongside JAM-2 as a direct head-to-head competitor in Galux's May 2026 comparative study; competes for the same pharma co-development deals in de novo antibody design.
- Generate Biomedicines: US-based generative biology company founded by Flagship Pioneering building a platform for de novo protein therapeutics design. Direct competitor in AI-driven antibody and protein design with major pharma partnerships.
- Iambic Therapeutics: AI-driven drug discovery company (formerly Entos) building physics-informed ML platforms for de novo antibody and small-molecule design. Closely comparable in technical approach (physics + AI) and stage, with pharma partnerships.
- Profluent Bio: US-based AI protein design company founded by Salesforce researchers, focused on de novo functional protein generation using large language models. Direct competitor in AI-driven protein engineering for therapeutics.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's AlphaFold to drug design. Operates at much larger scale than Galux with major pharma partnerships (Eli Lilly, Novartis) and represents the most capitalized competitor in AI protein design.
- AbCellera Biologics: Canadian public antibody discovery platform company with established pharma partnerships. Comparable as a horizontal antibody-discovery platform, though its technology stack emphasizes high-throughput wet-lab screening rather than pure de novo AI design.
- Insilico Medicine: Hong Kong-headquartered AI drug discovery company with Pharma.AI platform covering target discovery, generative chemistry, and clinical trial prediction. Broader scope than Galux but competing for the same AI-driven drug discovery budget pool at major pharma.
Emerging players
- EvolutionaryScale: Early-stage AI protein foundation model company founded by former Meta AI researchers. Emerging competitor with frontier-scale models for protein design; overlap with GaluxDesign's generative AI capability.
- Cradle Bio: Amsterdam-based AI protein engineering company with platform for designing antibodies, enzymes, and other proteins. Comparable as a generative biology platform though currently focused more on industrial biotech applications than pure therapeutics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights6 records
Customer concentration
Galux social profiles
Digital presenceGalux financial estimates
Financial estimateRevenue estimate
Valuation estimate
Galux leadership team
Management profileNumber of profiles
Profiles6 records
Galux funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Galux M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Galux
What does Galux do?
Galux develops and operates GaluxDesign, a proprietary AI platform that integrates artificial intelligence with physics-based principles to design therapeutic proteins from scratch (de novo protein design). The platform is modality-agnostic and is delivered to pharmaceutical partners through co-development agreements, joint research collaborations, and licensing arrangements to accelerate discovery of antibody therapeutics for autoimmune diseases, cancer, and rare/incurable diseases.
Is Galux a public or private company?
Galux is a private company. It is classified as venture growth investor backed and is currently operating.
When was Galux founded?
Galux was founded in 2020. It employs 11 to 50 people.
Where is Galux based?
Galux is headquartered in Dogokdong, South Korea, in the Asia region.
How does Galux make money?
Two revenue lines are on record. Co-development and Research Partnerships are the primary driver. The others are AI Platform Licensing and Services.
Who are Galux's main competitors?
Direct peers on record are Nabla Bio, Chai Discovery, Generate Biomedicines, Iambic Therapeutics and Profluent Bio. Broad incumbents are Isomorphic Labs, AbCellera Biologics and Insilico Medicine. Emerging players are EvolutionaryScale and Cradle Bio.
Does Galux have an API?
No public API is recorded for Galux.
What industry is Galux in?
Galux's product category is AI Drug Discovery / Computational Protein Design. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7372.